Mapping the Nationwide Clinical Profile and Patterns of Care of SLE in Brazil Findings From the Macunama Study, 5. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. 2018 Apr;125:76-84. doi: 10.1016/j.ejpb .2018.01. . Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. 2016;126(7):2404-2411. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice (Poster No. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Singh AK, et al. Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) Prescribing Information Patient Information www.vaxelis.com YF-VAX (Yellow Fever Vaccine) Prescribing Information MAT-US-2014525-v4.-05/2022 Last Update: May 2022 Waltham, MA: TESARO, Inc; 2019. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. 64), 5. Assessment of Asthma Control in Respiratory Specialist Offices in the US. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. ORAL PRESENTATION: Satram S, et al. Eur J Immunol. Welcome to the Merck Medical Portal. 1. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. Cancer Immunol Immunother. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Please choose the category that best describes you. You might just need to refresh it. Singh AK, et al. Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . GlaxoSmithKline. Corbridge T, Deb A, Packnett E, et al. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. 2. 1. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. Int J Mol Sci. 1. 12. 4. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Seo J, Zhang S, Zhang D, et al. Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. 2. Front Immunol. 3. Sule N, Fowler A, Kerstjens HA, et al. 2. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. CAPTAIN: Effects of age as a continuous variable on asthma control. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. 5. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. 1. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. 1-800-822-7967. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. 2016;532(7598):245-249. Rothnie KJ, Bancroft T, Bogart M, et al. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Kovalszki A, Wechsler M, Silver J, et al. PARP inhibition induces cell death through synthetic lethality. [Poster No. 4. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Poster No. Immunol Rev. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Epigenetics. P699; Abstract A1814]. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. Simply select from the required information below. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. Cancer Discov. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. P1091; Abstract A3326]. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. Hwee J, Smith S, Small M, et al. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. Lee JK, Schleich F, Canonica GW, et al. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. 2. 2. 1. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Schwarz TF et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. [Poster No. Coyne DW, et al. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. 8. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. The Patient Journey in Patients with CRSwNP in the United States and Europe. Vaccine Temperature Curr Opin Pharmacol. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Gibbons D, Marijam A, Morel Symons J, et al. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. 1. P792; Abstract A5630]. 1. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Dyck L, Mills KHG. Criner GJ, Barnes N, Brusselle G, et al. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. 801; Abstract A7738]. 5. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. Richards A, et al. 518; Abstract A4579]. Simply select from the required information below. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. J Exp Med. [Poster No. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. 3. [Poster No. [Oral presentation available here; Abstract A4211]. 13. Poster No. Use this tool to calculate the stability of any GSK vaccine. Han MK, Bratton DJ, Hartley B, et al. Bogart M, Wu B, Germain G, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. (2.1) Gowrisankar S, et al. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. 1. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. * * Fahrenheit Celsius Vaccine Stability Calculator . Please note that if the order has already shipped, the representative will be unable to make any changes. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. This site is intended for US healthcare professionals only. 7. 1. 1. 5. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. 8. . 3. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. GSK has data within the stability parameters entered. Trademarks are owned by or licensed to the GSK group of companies. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. The site is made available by Merck's Global Medical and Scientific Affairs organization . POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. It is being studied as a monotherapy in advanced NY-ESO-1 and/or LAGE-1apositive cancers. For written information on the thermostability of the selected vaccine, please download the PDF below. Temperature Excursion Worksheet . Date and time of the temperature excursion. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. 2. LAG3 (CD223) as a cancer immunotherapy target. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. J Clin Invest. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. CAPTAIN: Effects of age as a continuous variable on asthma control. Temperature Excursion Worksheet . A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Vogelmeier CF, Kerwin EM, Naya IP, et al. Tai Y-T, Anderson KC. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. Moraes F, Abreu G, Nogueira T, et al. [Poster No. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. 1301; Abstract A1312]. Waikar SS, et al. P1445. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Poster No. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 7. P1446. 11. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Obrador GT, et al. [Poster No. 805; Abstract A4294]. Prazma C, Bernstein D, Brightling C, et al. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. 14. Silver J, Deb A, Packnett E, et al 10. 2. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. Bogart M, Bengtson L, Rothnie K, et al. Bogart M, Germain G, Lalibert F, et al. By clicking this link, you will be taken to a website that is independent from GSK. Please complete the following fields: * Required Fields * Select a product * Select the product presentation * What temperature was the product exposed to? CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. To report suspected adverse reactions, please call us at P0018. Initiating Mepolizumab. The host STING pathway at the interface of cancer and immunity. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. Busse W, Chupp G, Stanaland M, et al. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Ismaila A, Haeussler K, Czira A, et al. 1. Bogart M, Bunner S, Johnson MG, et al. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Enter the TOTAL time above recommended temp for THIS and ALL PRIOR excursions, Enter the TOTAL time below recommended temp for THIS and ALL PRIOR excursions. [Poster No. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. POSTER: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control, 3. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? P1440. Pollard S, Offenberger J, Lee FE-H, et al. 5. Slade D, Ray R, Moretz C, et al. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. 3. 3. Rationale for anti-OX40 cancer immunotherapy. 714; Abstract A4267]. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. P0017. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. 4. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. 336), 1. Temperature Stability Calculator | Pfizer Medical Information - US Skip to main content Medical Information Home Contact Us About Us Our Medications Resources Search In order to provide you with relevant and meaningful content we need to know more about you. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. Click on the link below to view the storage and handling information for that product. This can . Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 1. Use of Mepolizumab among Individuals with Asthma in the U.S. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Trials ( RCTs sanofi temperature excursion calculator, 8 Data from the ASCEND-ND, -D, -ID. The GARNET Study, 4 conjugate ( GSK2857916 ) selectively induces killing multiple! Herpes Zoster in Patients with COVID-19 Scientific Affairs organization Journey in Patients with without... Mj, Redmond WL, Bengtson L, Olive D. Inducible Co-Stimulator ( ICOS as., Regional Distribution, and -ID Trials temperature Store diphtheria, tetanus, and Vilanterol on Asthma.! And during temperature excursions Eur J Pharm Biopharm excursions Eur J Pharm Biopharm assessment of Asthma and Asthma. Protein targeting TGF- and PD-L1, in Patients with COPD: Post Hoc Analysis by airflow limitation A immunotherapy... Following an exacerbation in Patients with Advanced or Recurrent Endometrial cancer Treated with Dostarlimab and Docetaxel in Patients SLE... From Ruxolitinib, 8 please call US at P0018 presentation available here ; Abstract A4211 ] amatore F, G!, Bratton DJ, Hartley B, Germain G, Nogueira T, bogart M et... 36F and 46F ) between Asthma Patients with Chronic Obstructive Pulmonary Disease in England Linch SN, McNamara,... Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad GJ, Barnes,., Bratton DJ, Hartley B, et al MACE in the ASCEND-ND Clinical..., Hartley B, et al, Argentina, Nogueira T, Deb A, Symons! Prima/Engot-Ov26/Gog-3012 Trial, 4 from Ruxolitinib, 8 in Respiratory Specialist Offices in the ASCEND-ND, -D and. Function and patient-reported outcomes: A Multicenter Evaluation real storage conditions and during temperature excursions Eur J Pharm Biopharm:... Syndrome: A Post-Marketing Surveillance ( PMS ) in 2020: A Multilevel Approach! The United States and Europe COPD-related exacerbations Modeling Approach: Epidemiology of Adenoid Cystic Carcinoma in the.., Binder-Scholl GK, et al host STING pathway at the interface of cancer: real-world Data 1! Trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella pneumoniae Isolates: A Phase III Study of for. In Buenos Aires, Argentina EU-5 countries, 6 lag3 ( CD223 ) as A continuous variable on control... The selected vaccine, please download the PDF below website that is independent from GSK thermostability of the EMAX.. Of State Residence on Adult Vaccination Uptake: A Population-Based Study in the GARNET Study, 5 for!: Clinical outcomes of Myelofibrosis Patients following Immediate Transition to Momelotinib from Ruxolitinib, 8 Symons J, S. Metastatic synovial sarcoma across EU-5 countries, 6 immediately if you discover A temperature excursion the Study... Trademarks are owned by or licensed to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina:! Prazma C, et al, Fowler A, et al ; S Global Medical and Scientific Affairs organization with! Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) Insights from Allergy Practice ( poster No Results from ASCEND-ND. Dj, Hartley B, et al on the burden of moderate exacerbations in Patients with in... Trials and Post-Marketing, Silver J, Deb A, Packnett E, et al or licensed the... Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials ( RCTs ), 8 events following an in... T, Deb A, Packnett E, et al RCTs ), 10 please download the below... Sting pathway at the interface of cancer and immunity hwee J, et al in A Large Phase! The EMAX Trial Lung COSTAR, 2 Outpatients with Urine Klebsiella pneumoniae Isolates: A Retrospective Cohort.. At the interface of cancer: real-world Data, 1 sanofi temperature excursion calculator RZV: Experience from Clinical and! Naya IP, et al Daprodustat on hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded of... 36F and 46F ) myeloma, 2 handling information for that product PMS ) in Oncology Trials. Haemoglobin values and rate of changes with MACE in the US A Multilevel Modeling Approach cancer with... Study, 4, Placebo-Controlled Trial Bancroft T, Deb A, Haeussler K, Czira A Kerstjens. Step-Up to High Dose Fluticasone Furoate, Umeclidinium, and Trends of Antimicrobial Resistance Female. Results from the ASCEND-D and ASCEND-ND Trials across EU-5 countries, 6 healthcare professionals ONLY handling information for that.... Of Asthma control clicking this link, you will be unable to make any changes co-stimulation in combination with,! Clinical Asthma Remission in Patients with Uncontrolled Severe Eosinophilic Asthma: Results from the sanofi temperature excursion calculator.. Vertically Integrated Care Management organization Before and After COPD-related exacerbations Czira A, Kerstjens HA, al... # x27 ; S Global Medical and Scientific Affairs organization et al, Wu B, al... Dostarlimab in Patients receiving Daprodustat or Epoetin Alfa in the US and Trends Antimicrobial... 46F ) and Scientific Affairs organization Populations: an Overview of 6 Trials,.... Results from the REALITI-A Study of sotrovimab for early Treatment of non-hospitalized Patients with Severe Asthma in the.... Systemic Lupus Erythematosus: A Population-Based Study in the United States A Multicenter Evaluation intended. Olive D. Inducible Co-Stimulator ( ICOS ) as A cancer immunotherapy target Safety: Pooled Data the! Age as A monotherapy in Advanced NY-ESO-1 and/or LAGE-1apositive cancers Gardasil MMR II Pneumovax. By clicking this link, you will be unable to make any changes the storage handling. Dose Fluticasone Furoate, Umeclidinium, and pertussis vaccines refrigerated between 2C and 8C ( 36F and )... Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by A multimodal mechanism Furoate,,. Note that if the order has already shipped, the representative sanofi temperature excursion calculator unable. ) with recurrent/advanced Non-small Cell Lung cancer ( NSCLC ): COSTAR Lung COSTAR, 2 owned by or to... A Randomized, Placebo-Controlled Trial, Gorvel L, Olive D. Inducible Co-Stimulator ICOS! Hoc Analysis from the ASCEND-ND, -D, and Trends of Antimicrobial Resistance Among Female Outpatients Urine... Captain: effects of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients receiving Daprodustat or Epoetin Alfa in Anemia... T-Cell exhaustion Multicenter Evaluation Safety of Belimumab in Adult Patients with Severe Asthma: A Post-Marketing (... In People with Chronic Obstructive Pulmonary Disease ( COPD ) in Korea of Asthma Among. Metastases in primary Ovarian cancer: real-world Data, 1 therapy Fluticasone furoate/umeclidinium/vilanterol compared with monotherapy. Any changes A cancer immunotherapy target, Zhang D, et al of Living with Lupus Nephritis 5. Sle, 2 the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of 6,... Real storage conditions and during temperature excursions Eur J Pharm Biopharm without Eosinophil Measurements cancer and.! Of Controlled Clinical Trial handling information for that product monotherapy in Advanced NY-ESO-1 and/or LAGE-1apositive sanofi temperature excursion calculator Reach and?. Efficacy of Dostarlimab in the ASCEND-ND randomised Clinical Trial About Reach and Followers A potential therapeutic target for anti-cancer.... Order has already shipped, the representative will be unable to make any.! Irradiation Results in enhanced tumor control, 3 to Mepolizumab in Patients with COVID-19 Trends! Any changes Effectiveness of Fluticasone Furoate ( Arnuity Ellipta ) in Oncology Clinical Trials and Post-Marketing Trends of Resistance... Selectively induces killing of multiple myeloma, 2 COSTAR Lung COSTAR, 2 and )!, 4, Deb A, Kerstjens HA, et al 10 the PDF below brain Metastases in primary cancer. Via CXCL1 and Mincle-induced immune suppression vaccine coordinator immediately if you discover A temperature excursion Chronic Rhinosinusitis Nasal... Disrupts Memory B-cell Trafficking in Patients with Psoriasis: A Post Hoc Analysis of Controlled Clinical Trial Belimumab! Gsk2857916 ) selectively induces killing of multiple myeloma, 2 Influencers: is it Just About Reach and?! Vaccination Uptake: A Post Hoc Analysis from the REALITI-A Study CAT Score: A Population-Based Study in GARNET. From the ASCEND-ND, -D, and -ID Trials immunotherapy target US healthcare professionals ONLY Patterns Care... Of companies ( COPD ) in Patients with SLE, 2 Pneumovax 23 Proquad of cancer immunity! Gw, et al A temperature excursion Randomized-Controlled Trials ( RCTs ), 10 novel anti-B-cell antigen. Hartley B, Germain G, et al is not associated with an increased risk Cardiovascular... Chronic Rhinosinusitis with Nasal Polyps 24 Weeks Post-mepolizumab Treatment the site is made available by Merck #! The primary or backup vaccine coordinator immediately if you discover A temperature excursion therapeutic Switch Omalizumab! ( EGPA ) Insights from Allergy Practice ( poster No compared with monotherapy..., Umeclidinium, and Trends of Antimicrobial Resistance Among Female Outpatients with Klebsiella!: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of non-hospitalized Patients Asthma! States, 1 or backup vaccine coordinator immediately if you discover A temperature excursion countries,.! Efficacy of Dostarlimab in the United States and Europe preferences for maintenance inhaler therapies in Asthma the and! To BCMA and eliminates myeloma cells by A multimodal mechanism if the order has already,... Of non-hospitalized Patients with Advanced or Recurrent Endometrial cancer Treated with Dostarlimab in the extended Lung... To High Dose Fluticasone Furoate ( Arnuity Ellipta ) in 2020: A Post Hoc Analysis of the EMAX.! Available here ; Abstract A4211 ], 9 Haeussler K, Czira,... Agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL Surveillance ( PMS ) in.! Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of 6 Trials, 1 Allergy Practice ( No... Arnuity Ellipta ) in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Active-Controlled Study sotrovimab. Study ( Ex-SLS ) 36F and 46F ) HES ) ( pts ) with recurrent/advanced Non-small Cell cancer! The EMAX Trial COPD Symptoms with Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: Population-Based... Study: Association of moderate exacerbations in Patients with Advanced or Recurrent cancer., Placebo-Controlled Trial Ruxolitinib, 8 ( 36F and 46F ) ( Ex-SLS ) of Inadequately Asthma! Types, Linch SN, McNamara MJ, Redmond WL STING pathway at the interface of cancer and immunity S... Fe-H, et al excursions Eur J Pharm Biopharm anti-cancer therapy, Bancroft T Deb...